Rapid Diagnosis of Community Acquired Pneumonia

Laboratory products

Rapid Diagnosis of Community Acquired Pneumonia

29 Jan, 2008

Published over 18 years ago. See the latest and most current information on Laboratory products.

Inverness Medical Professional Diagnostics
1 min read

Across Europe and the US, Community Acquired Pneumonia (CAP) affects 100 per 100,000 adults a year with a mortality rate of 10-20%, say the WHO.
Inverness Medical Professional Diagnostics has responded to the need to rapidly and accurately diagnose CAP by introducing BinaxNOW® S. pneumoniae and Legionella, part of the BinaxNOW® range of rapid respiratory tests. The simple, swab based BinaxNOW S. pneumoniae and Legionella immunochromatographic assays provide clear reliable results in as little as 15 minutes from urine samples.

Through BinaxNOW’s ability to test and provide patients with their results in one visit, healthcare professionals can ensure the most appropriate treatment is administered without delay and that hospitalisation and potentially life threatening complications are avoided.

The BinaxNOW range of rapid tests for respiratory infections covers Influenza A and B, Legionella, RSV, Strep A and S. pneumoniae. With an easy to use patented book-shaped test device, Inverness Medical continues to enable early and accurate diagnosis of disease with its BinaxNOW rapid tests.

Latest News

ILM 51.6 Sept 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
New dust monitoring technology targets hazardous industrial environments
Explore more Arrow
Pollution Solutions Online
Safe drinking water worldwide
Explore more Arrow
Petro Online
Independent studies strengthen the evidence for quantitative optical gas imaging
Explore more Arrow
Chromatography Today
Inline degasser range upgraded with new vacuum control and pump technology
Explore more Arrow